{"id":5617,"date":"2024-06-13T16:26:41","date_gmt":"2024-06-13T16:26:41","guid":{"rendered":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/?p=5617"},"modified":"2024-06-14T01:09:35","modified_gmt":"2024-06-14T01:09:35","slug":"carvill","status":"publish","type":"post","link":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/2024\/06\/13\/carvill\/","title":{"rendered":"Gemma Carvill, PhD"},"content":{"rendered":"<p><img decoding=\"async\" class=\"lazyload alignnone size-full wp-image-5618\" src=\"http:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Gemma-Carvill.png\" data-orig-src=\"http:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Gemma-Carvill.png\" alt=\"\" width=\"300\" height=\"300\" srcset=\"data:image\/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27300%27%20height%3D%27300%27%20viewBox%3D%270%200%20300%20300%27%3E%3Crect%20width%3D%27300%27%20height%3D%27300%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E\" data-srcset=\"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Gemma-Carvill-66x66.png 66w, https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Gemma-Carvill-150x150.png 150w, https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Gemma-Carvill-200x200.png 200w, https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Gemma-Carvill.png 300w\" data-sizes=\"auto\" data-orig-sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>Gemma Carvill is an Assistant Professor in the Department of Neurology at Northwestern University. Her lab uses genomic technologies to define the molecular basis of epilepsy, including coding and non-coding variants. She integrates computational modeling with high-throughput assays of variant effect and detailed mechanistic studies in patient-derived stem cell models, with a focus on epigenetic mechanisms. At Northwestern, Dr. Carvill interfaces with the adult and pediatric clinical teams to expand neurogenetics research and to facilitate genetic diagnoses for patients and families. She is also committed to building epilepsy genomics infrastructure and accessibility to precision therapies in her home country, South Africa.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gemma Carvill is an Assistant Professor in the Department of Neurology at Northwestern University. Her lab uses genomic technologies to define the molecular basis of epilepsy, including coding and non-coding variants. She integrates computational modeling with high-throughput assays of variant effect and detailed mechanistic studies in patient-derived stem cell models, with a focus on epigenetic [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5618,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[],"class_list":["post-5617","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-creative"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/posts\/5617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/comments?post=5617"}],"version-history":[{"count":1,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/posts\/5617\/revisions"}],"predecessor-version":[{"id":5619,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/posts\/5617\/revisions\/5619"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/media\/5618"}],"wp:attachment":[{"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/media?parent=5617"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/categories?post=5617"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/tags?post=5617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}